- Home
- DEA vs CDNA Comparison
DEA vs CDNA Comparison
Compare DEA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- CDNA
- Stock Information
- Founded
- DEA 2011
- CDNA 1998
- Country
- DEA United States
- CDNA United States
- Employees
- DEA N/A
- CDNA N/A
- Industry
- DEA Real Estate Investment Trusts
- CDNA Medical Specialities
- Sector
- DEA Real Estate
- CDNA Health Care
- Exchange
- DEA Nasdaq
- CDNA Nasdaq
- Market Cap
- DEA 912.0M
- CDNA 844.7M
- IPO Year
- DEA 2015
- CDNA 2014
- Fundamental
- Price
- DEA $20.74
- CDNA $16.02
- Analyst Decision
- DEA Hold
- CDNA Buy
- Analyst Count
- DEA 4
- CDNA 7
- Target Price
- DEA $29.06
- CDNA $30.33
- AVG Volume (30 Days)
- DEA 721.7K
- CDNA 1.2M
- Earning Date
- DEA 04-29-2025
- CDNA 04-30-2025
- Dividend Yield
- DEA 6.01%
- CDNA N/A
- EPS Growth
- DEA N/A
- CDNA N/A
- EPS
- DEA 0.41
- CDNA 1.07
- Revenue
- DEA $314,385,000.00
- CDNA $346,421,000.00
- Revenue This Year
- DEA $7.23
- CDNA $13.37
- Revenue Next Year
- DEA $7.93
- CDNA $15.28
- P/E Ratio
- DEA $50.82
- CDNA $14.89
- Revenue Growth
- DEA 6.82
- CDNA 25.92
- 52 Week Low
- DEA $19.33
- CDNA $7.42
- 52 Week High
- DEA $36.31
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- DEA 43.21
- CDNA 44.16
- Support Level
- DEA $20.53
- CDNA $14.09
- Resistance Level
- DEA $21.09
- CDNA $16.67
- Average True Range (ATR)
- DEA 0.64
- CDNA 0.98
- MACD
- DEA 0.26
- CDNA 0.06
- Stochastic Oscillator
- DEA 70.49
- CDNA 41.77
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.